Top 10 Companies in the (S)-MEPHENYTOIN (CAS 18601) Market (2026): Market Leaders Powering Global Pharmacogenomics

MARKET INSIGHTS

Global (S)-Mephenytoin (CAS 18601-23-5) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-Mephenytoin is a chiral pharmaceutical compound and the S-enantiomer of mephenytoin, a hydantoin-class anticonvulsant. It is widely recognized in pharmacological research as a selective substrate for the cytochrome P450 2C19 (CYP2C19) enzyme, making it an invaluable reference standard and research chemical in drug metabolism studies, pharmacokinetic profiling, and phenotyping assays. Its role in identifying CYP2C19 polymorphisms has cemented its relevance across clinical pharmacology and precision medicine applications.

The market is witnessing steady growth driven by the expanding scope of pharmacogenomics research, increasing demand for high-purity reference standards in drug development pipelines, and rising adoption of metabolic phenotyping in clinical trials. Furthermore, the growing emphasis on personalized medicine and the identification of poor metabolizer populations globally continue to reinforce demand for (S)-Mephenytoin as a critical research tool. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), Toronto Research Chemicals, and Cayman Chemical Company.

(S)-MEPHENYTOIN (CAS 18601) Market – View in Detailed Research Report

1️⃣ Toronto Research Chemicals (TRC)

Headquarters: Toronto, Canada
Key Offering: High‑purity (S)-Mephenytoin (≥98%), isotopically labeled variants, custom formulated grades

TRC has positioned itself as a leading provider of chiral reference standards for CYP2C19 phenotyping. Their rigorous chiral HPLC validation and ISO 17034 certification ensure consistent enantiomeric purity, meeting the stringent requirements of GLP‑compliant ADME studies.

Sustainability & Growth Initiatives:

• Investing in green chemistry approaches for chiral resolution to reduce solvent usage.
• Expanding global distribution networks to support emerging markets in Asia‑Pacific.
• Offering bundled metabolite reference standards (4’-hydroxymephenytoin) for LC‑MS/MS assay development.

2️⃣ Cayman Chemical

Headquarters: St. Louis, USA
Key Offering: Reference standard (S)-Mephenytoin, isotopically labeled compounds, custom purity grades

Cayman Chemical’s extensive analytical portfolio and robust quality systems enable rapid turnaround for research laboratories worldwide. Their focus on high‑purity standards supports pharmaceutical companies’ regulatory submissions.

Sustainability & Growth Initiatives:

• Adopting renewable energy sources in manufacturing facilities.
• Partnering with academic institutions for CYP2C19 pharmacogenomics studies.
• Providing API‑grade and reference‑grade products under a single supply chain.

3️⃣ Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany / St. Louis, USA
Key Offering: High‑purity (S)-Mephenytoin, isotopically labeled standards, custom formulations

With a global life‑science portfolio, Sigma‑Aldrich delivers (S)-Mephenytoin with comprehensive chain‑of‑custody documentation, meeting USP/EP regulatory standards. Their ISO 17034 certification underpins reliability for pharmaceutical and academic users.

Sustainability & Growth Initiatives:

• Implementing circular waste‑management protocols.
• Expanding partnerships with CROs to streamline assay development.
• Investing in advanced chiral synthesis technologies to reduce production costs.

4️⃣ Biosynth

Headquarters: Basel, Switzerland
Key Offering: Custom chiral synthesis, high‑purity (S)-Mephenytoin, isotopically labeled variants

Biosynth specializes in bespoke synthesis of chiral intermediates, providing tailored solutions for pharmaceutical R&D and academic research. Their focus on process optimization reduces lead times for niche research chemicals.

Sustainability & Growth Initiatives:

• Adopting biocatalytic synthesis routes for lower environmental impact.
• Collaborating with universities to develop next‑generation chiral catalysts.
• Expanding their product catalog to include other CYP probe substrates.

5️⃣ Santa Cruz Biotechnology

Headquarters: Dallas, USA
Key Offering: Research‑grade (S)-Mephenytoin, custom purity grades

Santa Cruz Biotechnology offers a cost‑effective solution for academic laboratories, providing high‑purity standards with detailed analytical data. Their focus on educational outreach supports training in drug metabolism research.

Sustainability & Growth Initiatives:

• Reducing packaging waste through recyclable materials.
• Providing open‑access analytical data for community validation.
• Partnering with global universities for joint research projects.

6️⃣ Alsachim (Shimadzu Group)

Headquarters: Bunkyo, Japan
Key Offering: High‑purity (S)-Mephenytoin, isotopically labeled standards, custom formulations

Alsachim leverages Shimadzu’s analytical expertise to deliver (S)-Mephenytoin with comprehensive spectral data. Their strong presence in Asia‑Pacific supports regional demand for CYP2C19 phenotyping.

Sustainability & Growth Initiatives:

• Integrating renewable energy in production facilities.
• Collaborating with Japanese regulatory bodies to streamline approval processes.
• Offering educational webinars on CYP2C19 assay development.

7️⃣ Medical Isotopes, Inc.

Headquarters: Cincinnati, USA
Key Offering: Isotopically labeled (S)-Mephenytoin (D3), custom purity grades

Medical Isotopes specializes in deuterium‑labeled reference standards, providing essential internal standards for quantitative LC‑MS/MS assays in pharmacokinetic studies.

Sustainability & Growth Initiatives:

• Optimizing isotope production to reduce carbon footprint.
• Expanding supply of rare isotopes for emerging research needs.
• Partnering with CROs for turnkey assay kits.

8️⃣ Luminex

Headquarters: Austin, USA
Key Offering: Genotyping panels for CYP2C19, CYP450 phenotyping chips

Luminex’s multiplexed genotyping platforms provide complementary data to (S)-Mephenytoin phenotyping, enabling integrated pharmacogenomic profiling in clinical trials.

Sustainability & Growth Initiatives:

• Developing low‑cost, high‑throughput genotyping assays.
• Collaborating with pharmaceutical companies to integrate phenotyping and genotyping data.
• Investing in AI‑driven data analytics for personalized medicine.

9️⃣ Thermo Fisher Scientific

Headquarters: Waltham, USA
Key Offering: Genomics and proteomics platforms, CYP2C19 phenotyping kits

Thermo Fisher offers a suite of analytical instruments and reagents, including CYP2C19 phenotyping kits that complement (S)-Mephenytoin probe studies.

Sustainability & Growth Initiatives:

• Reducing single‑use plastic in reagent kits.
• Providing open‑source software for assay data analysis.
• Expanding global training programs for bioanalytical scientists.

🔟 10️⃣ Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Integrated drug development services, reference standards (S)-Mephenytoin

Merck KGaA’s comprehensive portfolio spans from early discovery to regulatory submissions, offering (S)-Mephenytoin as part of its reference standard suite. Their global R&D network supports large‑scale pharmacogenomics projects.

Sustainability & Growth Initiatives:

• Implementing carbon‑neutral manufacturing processes.
• Partnering with academia to accelerate CYP2C19 research.
• Developing digital platforms for real‑time assay monitoring.

Download FREE Sample Report: (S)-MEPHENYTOIN (CAS 18601) Market – View in Detailed Research Report

Get Full Report Here: (S)-MEPHENYTOIN (CAS 18601) Market – View in Detailed Research Report

Outlook: The Future of (S)-MEPHENYTOIN (CAS 18601) Market

The market is expected to continue its robust growth trajectory, driven by regulatory emphasis on CYP2C19 phenotyping in new drug applications and the expansion of bioanalytical CRO services. The Asia‑Pacific region will emerge as a key growth engine, while North America remains the largest market due to its mature pharmacogenomics infrastructure.

Future Trends Shaping the (S)-MEPHENYTOIN (CAS 18601) Market

• Integration of genotyping and phenotyping data for comprehensive CYP2C19 profiling.
• Adoption of isotopically labeled standards in quantitative LC‑MS/MS assays.
• Expansion of green chemistry approaches in chiral synthesis.
• Growth of personalized medicine programs requiring high‑purity reference standards.
• Increased collaboration between academic institutions and industry for CYP2C19 research.